ClinicalTrials.gg
RecruitingNCT06442592CATAMARAN PedUpdated Apr 3, 2026

Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects

An interventional study of Blood sampling and Assessment of neurodevelopment (CA) in Congenital Heart Defects and Neurodevelopmental Disorder, sponsored by Nantes University Hospital. Recruiting at 5 sites in France. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,206
Allocation
Non-randomized
Ages
3 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.

Planned enrollment
2nd of 34
1,206 · median 91
Started
2024
with 2 others
No phase
27 of 73
11 open now
Primary completion
2027-07
later than 12 of 21 live
Registered
59th of 73
by date
Lead sponsor
5 of 73
Nantes University Hospital

Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 2nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2024, is one of 27 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 59th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 3 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Heart Defects, Congenital with a site in France, or all of them as a file.
02

Study summary

The leading cause of birth defects, Congenital Heart Defects (CHD) affect 12 million people worldwide and 41,000 newborns/year in Europe. It's a major cause of life-long morbidity and mortality, and a crucial public health issue. More than 50% of childs born with critical CHD will develop Neurodevelopmental Disorders (NDs), requiring specific care and impairing quality of life. NDs corresponds to early and lasting disturbances in cognitive, affective and behavioral development, linked to abnormalities in brain development. They are heterogeneous, affecting language, learning, motor skills, intellectual efficiency, social cognition, attention, memory and executive functions, and are associated with psychosocial difficulties (adaptive behavior, social interactions). This hidden handicap is the main long-term sequels of CHD, even before cardiovascular sequels, in individuals who often underwent multiple heart operations in early childhood. NDs concern not only complex CHD, but also simple CHD repaired in childhood and considered cured.

The origin of TND associated with CHD is largely unknown. To date, few genetic or environmental causes have been clearly identified, but recent work has suggested that a common origin may link cardiac malformation and neurodevelopmental abnormality.

The CATAMARAN - Pediatrics project is designed to detect potential neurodevelopmental delays associated with CHD as early as age 3, and to identify individual susceptibility factors involved in the occurrence of NDs in CHD children.

03

Conditions studied

  • Congenital Heart Defects
  • Neurodevelopmental Disorder

Keywords

  • Congenital Heart Defects
  • Neurodevelopmental Disorder
  • Genetics
04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child (aged 3 to 11) with critical MCC operated on for heart surgery during the first three months of life
  • Parents and child affiliated with or benefiting from a social security or similar scheme
  • Parents' and child's good understanding of the French language
  • Free, informed and written consent of both parents for themselves and for the child
  • Free, informed and written consent of the child aged 6 and over
  • Biological parents

Exclusion criteria

Exclusion Criteria:

  • Genetic anomaly or malformative syndrome associated with neurodevelopmental abnormalities, identified prior to inclusion
  • Neurodevelopmental assessment not practicable
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,206 participants (estimated)

Study arms

  • Other
    CATAMARAN - Pediatrics - Interdisciplinary programme - Nantes Only

    The study population will consist of 201 children aged 3 to 11 and their two parents.

    Other: Blood sampling · Diagnostic Test: Assessment of neurodevelopment (Nantes) · Other: Assessment of the parental stress

  • Other
    CATAMARAN - Pediatrics - Unique neuropsychological assessment Associated centers (including Nantes)

    The study population will consist of 201 children aged 3 to 11 and their two parents.

    Other: Blood sampling · Diagnostic Test: Assessment of neurodevelopment (CA) · Other: Assessment of the parental stress

Interventions

  • OtherBlood sampling

    An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.

  • Diagnostic testAssessment of neurodevelopment (CA)

    The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.

  • Diagnostic testAssessment of neurodevelopment (Nantes)

    The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.

  • OtherAssessment of the parental stress

    Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.

06

What researchers measure

Primary outcomes

  1. Assessment of the prevalence of neurodevelopmental disorders in children aged 3-11 years with critical congenital heart defects.

    Time frame: 14 days

Secondary outcomes

  1. Identify rare genetic variants associated with genome-wide neurodevelopmental disorders in patients with congenital heart defects.

    The presence of rare genetic variants associated with neurodevelopmental disorders will be determined by a 30X whole genome sequencing approach based on the association study of congenital heart defects with neurodevelopmental disorders versus congenital heart defects without neurodevelopmental disorders.

    Time frame: One day

  2. Identify frequent genetic variants associated with genome-wide neurodevelopmental disorders in patients with congenital heart defects.

    The presence of frequent genetic variants associated with neurodevelopmental disorders will be determined by a 30X whole genome sequencing approach based on the association study of congenital heart defects with neurodevelopmental disorders versus congenital heart defects without neurodevelopmental disorders.

    Time frame: One day

  3. Assessment of the prevalence of neurodevelopmental disorders in children with critical congenital heart defects in each age subgroup (3-5, 6-8, and 9-11 years).

    Time frame: up to 14 days

  4. Evaluate and describe the neurodevelopmental domains affected in the pediatric population of Nantes (Multidisciplinary assessment).

    Functional diagnosis of different types of NDD defined by at least one score deficient in relation to the test norm (-1.5 standard deviation or 90 percentile) in each age subgroup.

    Time frame: up to 14 days

  5. Assessment of the quality of life and psychopathological aspects of the child as well as parental stress.

    Proportion of children with impaired quality of life, psychopathological difficulties and proportion of adults with parental stress, compared with the test norm (-1.5 standard deviation or 90 percentile).

    Time frame: up to 14 days

  6. Assessment of diagnostic accuracy (of NDD) provided by an innovative multidisciplinary approach.

    Comparison of TND frequency in Nantes versus associated centers and description of differences between centers

    Time frame: up to 14 days

  7. Describe the different types of neurodevelopmental disorders (number and nature of neurodevelopmental domains affected) in each age subgroup (intelligence, oral language, motor skills, school learning, executive functions, social interactions).

    Time frame: up to 14 days

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Jul 8, 2024
Primary completionEst.
Jul 8, 2027
CompletionEst.
Aug 8, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06442592
Collaborators
Angers University
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 8, 2024
Primary completion
Jul 8, 2027 (estimated)
Completion
Aug 8, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Alban Baruteau
Contact
albanelouen.baruteau@chu-nantes.fr
02 40 08 77 42

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion